Impax Labs Inc (IPXL) 32.45 $IPXL Impax to Present at

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 1:04 AM

Impax Labs Inc (IPXL) 32.45 $IPXL

Impax to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Thu Jun 02, 3:10PM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, 2016 at 2:40 p.m. Pacific Time. The conference will be held in Rancho Palos Verdes, CA.
IPXL: 32.45 (-1.11)

Impax Labs reports 1Q loss
Automated Insights - Tue May 10, 5:48AM CDT
HAYWARD, Calif. (AP) _ Impax Laboratories Inc. (IPXL) on Tuesday reported a loss of $10.4 million in its first quarter.
IPXL: 32.45 (-1.11)

Impax Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 5:40AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today reported first quarter 2016 financial results for the quarter ended March 31, 2016.
IPXL: 32.45 (-1.11)

Is a Surprise Coming for Impax Laboratories (IPXL) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:48AM CDT
A positive Earnings ESP coupled with impressive Zacks Rank has made Impax Laboratories (IPXL) an interesting choice for the investors.
IPXL: 32.45 (-1.11)

Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 4:13PM CDT
Jazz Pharmaceuticals (JAZZ), which is set to report first-quarter 2016 results on May 10, delivered a positive earnings surprise of 36.75% last quarter.
IPXL: 32.45 (-1.11), CLSN: 1.40 (-0.02), JAZZ: 150.76 (-5.26)

What's in the Cards for Catalyst (CPRX) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 11:18AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) is scheduled to report first-quarter 2016 results on May 10.
IPXL: 32.45 (-1.11), CPRX: 0.62 (-0.03), JAZZ: 150.76 (-5.26), XON: 25.27 (+0.14)

Intrexon (XON): Stock Likely to Beat Estimates in Q1 Earnings
Zacks Equity Research - Zacks Investment Research - Thu May 05, 5:49PM CDT
Intrexon (XON), which is set to report first-quarter 2016 results on May 10, delivered a positive surprise of 5.56% last quarter.
IPXL: 32.45 (-1.11), FCSC: 1.17 (-0.07), JAZZ: 150.76 (-5.26), XON: 25.27 (+0.14)

Will BioDelivery (BDSI) Disappoint Estimates in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 5:47PM CDT
BioDelivery Sciences (BDSI), which is set to report first-quarter 2016 results on May 10, reported a negative earnings surprise of 63.64% last quarter.
IPXL: 32.45 (-1.11), BDSI: 2.67 (-0.18), ENDP: 16.48 (-1.52), JAZZ: 150.76 (-5.26)

What's in the Cards for Synta (SNTA) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 4:58AM CDT
Synta Pharmaceuticals (SNTA), which is expected to report first-quarter 2016 results on May 5, had posted a positive surprise of 21.52% last quarter.
IPXL: 32.45 (-1.11), SNTA: 0.35 (-0.01), JAZZ: 150.76 (-5.26), BIND: 0.40 (-0.01)

What Awaits Puma Biotechnology (PBYI) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:58PM CDT
Puma Biotechnology (PBYI) is expected to report first-quarter 2016 results on May 9.
IPXL: 32.45 (-1.11), JAZZ: 150.76 (-5.26), PBYI: 33.41 (-0.43)

Inovio (INO): What's in Store for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:03AM CDT
Inovio (INO) is scheduled to report first-quarter 2015 results on May 9, before the opening bell.
IPXL: 32.45 (-1.11), INO: 10.62 (-0.39), JAZZ: 150.76 (-5.26), AZN: 27.97 (-0.99)

What's in Store for Horizon (HZNP) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 9:40AM CDT
Horizon Pharma (HZNP), which is set to report first-quarter 2016 results on May 9, recorded a negative earnings surprise of 20% last quarter.
IPXL: 32.45 (-1.11), JAZZ: 150.76 (-5.26), HZNP: 17.88 (-0.65), BIND: 0.40 (-0.01)

Impax to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PR Newswire - Wed May 04, 7:15AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Tuesday, May 10, 2016 at 9:20 a.m. Pacific Time. The conference will be held in Las Vegas, NV.
IPXL: 32.45 (-1.11)

Conatus (CNAT): Can the Stock Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:57PM CDT
Conatus (CNAT) is scheduled to report first-quarter 2016 results on May 5, before market opens.
ZTS: 47.39 (-0.75), IPXL: 32.45 (-1.11), CNAT: 2.02 (-0.11), JAZZ: 150.76 (-5.26)

What's Up at GW Pharmaceuticals (GWPH) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:45PM CDT
GW Pharmaceuticals (GWPH), which is set to report second-quarter fiscal 2016 results on May 5, had posted a positive surprise of 34.78%.
ZTS: 47.39 (-0.75), IPXL: 32.45 (-1.11), GWPH: 89.69 (+0.24), JAZZ: 150.76 (-5.26)

What's in Store for Agios (AGIO) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:38PM CDT
Agios Pharmaceuticals (AGIO), which is set to report first-quarter 2016 results on May 5, delivered a negative surprise of 300% last quarter.
IPXL: 32.45 (-1.11), JAZZ: 150.76 (-5.26), AGIO: 50.35 (-5.87), CELG: 102.91 (-3.22)

Intercept (ICPT): Stock Likely to Disappoint in Q1 Earnings
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:43AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report first-quarter 2016 results on May 5, after the market closes.
IPXL: 32.45 (-1.11), JAZZ: 150.76 (-5.26), XON: 25.27 (+0.14), ICPT: 150.66 (-3.56)

Radius Health (RDUS): Stock to Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 3:51PM CDT
Radius Health, Inc. (RDUS) is scheduled to report first-quarter 2016 results on May 5.
IPXL: 32.45 (-1.11), RDUS: 36.64 (-0.05), JAZZ: 150.76 (-5.26), NVS: 78.94 (-1.57)

Endo (ENDP) Q1 Earnings: What's in Store for the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:58AM CDT
Endo International (ENDP), which is set to report first-quarter 2016 results on May 5, delivered a positive earnings surprise of 7.09% last quarter.
IPXL: 32.45 (-1.11), ENDP: 16.48 (-1.52), JAZZ: 150.76 (-5.26), GNCA: 3.94 (-0.28)

AmerisourceBergen (ABC) Q2 Earnings: Stock to Surprise?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:23AM CDT
AmerisourceBergen Corporation (ABC ) is set to report second-quarter fiscal 2016 results on May 5, before the opening bell.
IPXL: 32.45 (-1.11), ABC: 76.46 (+0.29), WBA: 82.47 (+3.46), JAZZ: 150.76 (-5.26)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rain Agent Vaults: Revolutionizing Payments with AI

Innovative Payments with AI Power Alright, folks, Rain's gone and done something that's probably going to shake things up in the payments world—'cause they've given AI agents the ability to handle money like never before. We're not just talking about some run-of-the-mill integration here. This is a genuine game changer, promising to make agents as financially savvy as...

ProBio, AbTis Forge Bond for Next-Gen Oncology ADCs

Deal or No Deal: ProBio's New Licensing Agreement In the ever-evolving realm of biopharmaceuticals, ProBio's recent handshake with South Korea's AbTis is stirring the pot. The shot-callers at ProBio are passing the baton to AbTis, giving them a crack at developing a thumping new therapeutic antibody asset aimed squarely at oncology targets. Pretty slick move if you ask...

Alogent's Unify Snags Award for Innovation and Impact

Innovation That Captures Attention Alogent sure did grab the spotlight with their Unify platform walking away with a Credit Union Times Luminaries Award. The name of the game here is deposit processing innovation—the kind of buzz that turns heads in the banking world. This recognition isn't just another plaque for the lobby; it's a testament to a significant stamp on...

Sokolove Law Wins $28.8M Verdict for Misdiagnosis Case

Jury Awards $28.8 Million in Misdiagnosis Case Well, here's a tale that's bound to ruffle some feathers in the medical community—$28.8 million tossed on the table because an emergency room missed a life-threatening aortic aneurysm. For the uninitiated, this isn't just chump change; it's the cost of dropping the ball when the stakes are as high as a human life. A jury in...

FirstDigital Expands Fiber Network in Utah and Arizona

Weaving a Web of Connectivity Let's talk about FirstDigital putting its shoulder to the wheel in Utah and Arizona. They're expanding their redundant fiber network to rope in more businesses under their umbrella of connectivity. This ain't just another dry IT endeavor—it's about building a safety net for our ever-connected world. The Stakes of Network Disruption You know...

Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Alyssa Bunch: Big Moves in Tennessee Real Estate

Navigating the Tennessee Real Estate Maze If you're talking about where the real estate action happens in Tennessee, you'd better mention Alyssa Bunch, the Vanderbilt-educated dynamo who turns the unforsale into the must-buy. Most of the deals she orchestrates are invisible to the public eye until they're all but written in ink and ready to reshape landscapes—or, more...

Bakersfield Sees Spike in Crashes Post Time Change

Evening Darkness and Safety Concerns Folks, it seems Bakersfield streets transform into a battlefield once the clock falls back. With darkness creeping in earlier, those evening hours right after the time change see a sobering uptick in accidents. According to an analysis by Chain | Cohn | Clark, pedestrian and bicyclist crashes from 5 to 7 p.m. double. It's not just...

IASO Bio's In Vivo CAR-T: A Game Changer for Oncology?

You ever feel like you're watching history happen right in front of you? That's the vibe with IASO Bio's latest move in the realm of oncology. This outfit just scored a major victory, getting China's NMPA and the U.S. FDA to greenlight their IASO208, a CD20-targeting in vivo CAR-T therapy. It's not every day you see a company land dual regulatory nods like...

Zephyr's Alto Hood: Redefining Kitchen Versatility

An Artist in the Kitchen Who knew a kitchen hood could be a canvas, right? Zephyr, always a punch above the ordinary in kitchen design, has pulled another rabbit out of their hat with the Alto Wall Custom Hood. Forget blending in; this piece is about standing out and shouting style—all while keeping your cooking area fresh. Options Galore The Alto Hood isn't about...